What is Ozanimod
Ozanimod is a novel oral immunosuppressant that is currently in development for the treatment of multiple sclerosis (MS) and ulcerative colitis (UC). Ozanimod selectively targets the S1P1 receptor, which is involved in the trafficking of lymphocytes out of the central nervous system (CNS). By selectively targeting the S1P1 receptor, Ozanimod is able to reduce inflammation in the CNS while leaving other tissues unaffected.
The development of Ozanimod is based on the findings of a phase 2 study that showed that treatment with Ozanimod resulted in a significant reduction in the number of new gadolinium-enhancing lesions on MRI scans in patients with relapsing-remitting MS. Additionally, a phase 3 study showed that treatment with Ozanimod was associated with a reduced risk of disease progression and disability in patients with relapsing-remitting MS.
Ozanimod is also being evaluated for the treatment
Benefits of Ozanimod
and Its Uses.
Ozanimod is a novel, oral, sphingosine 1-phosphate receptor modulator that is currently being evaluated for the treatment of relapsing multiple sclerosis (MS) and ulcerative colitis (UC).
In MS, ozanimod inhibits the migration of lymphocytes from the blood into the central nervous system, which may prevent disease progression.
In UC, ozanimod is thought to work by decreasing the production of inflammatory cytokines and chemokines.
Some potential benefits of ozanimod include:
1. Reduced relapse rates in MS
2. Improved patient outcomes in UC
3. Low incidence of adverse effects
4. Wide therapeutic window
Side Effects and Dosage of Ozanimod
Ozanimod is a novel, selective sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS). Ozanimod is a systemic, small molecule that selectively targets S1P receptors on cells in the immune system, which can impact the overall inflammatory response. Ozanimod has a favorable safety and tolerability profile with a low incidence of serious adverse events (SAEs), and it is generally well tolerated. The most common adverse effects are headache, nausea, and diarrhea.
The recommended dose of ozanimod is 0.5 mg administered orally once daily. The dose may be increased to 1 mg once daily if tolerated.